2013 - Optimising models for human lung diseases and drug development

Animal models, organ and cell cultures are critical to understand mechanisms and pathogenesis of pulmonary health and disease, and are indispensable in drug development. However, the pathogenetic and translational relevance of the models is often unclear. Further, the use of animals in medical research is becoming increasingly controversial from an ethical perspective.

The objectives of this seminar were to gather respiratory scientists and clinicians from different subspecialties to foster exchange and increase their knowledge about lung disease models. It is expected that better understanding of the available models, especially their benefits and their limitations, will facilitate better use of research resources and reduce the numbers of animals in pulmonary research, thereby enhancing the ethical standards of experimental pulmonary research.

2013 - Optimising models for human lung diseases and drug development

2024 - Sleep apnea and its consequences: from animal models to precision medicine

2023 - In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Animal models in drug development

B. Crestani (Paris, France)

Slides

Modeling in vitro, ex vivo or in vivo?

P. Mercer (London, United Kingdom)

Slides

Accompanying documents

Standardisation of animal models across centers - scientific necessity or ethical mandate?

E. White (Ann Arbor, United States of America)

Slides

Ins and outs of transgenic animals

W. Shi (Los Angeles, Ca, United States of America)

Slides

Accompanying documents

Morphometry and Stereology in lung tissue

H. Fehrenbach (Borstel, Germany)

Accompanying documents

Small animal imaging using CT, PET and MRI

R. Labiris (Hamilton - Ontario, Canada)

Slides

Accompanying documents

Microscopic Imaging of the lungs and other approaches to assess vascular permeability

W. Kuebler (Toronto, Canada)

Slides

Accompanying documents

Pulmonary fibrosis and ILD

P. Bonniaud (Dijon, France)

Slides

Accompanying documents

Acute lung injury

S. Uhlig (Aachen, Germany)

Accompanying documents

Acute and Chronic models for asthma/COPD

G. Joos (Ghent, Belgium)

Slides

Accompanying documents

Pulmonary Hypertension

C. Guignabert (Creteil, France)

Slides

Accompanying documents

CDN Connection Issue

2013 - Optimising models for human lung diseases and drug development

2013 - Optimising models for human lung diseases and drug development

#{title}